Zelira Therapeutics’ Financials: Borrowings Boost Cash Flow
Company Announcements

Zelira Therapeutics’ Financials: Borrowings Boost Cash Flow

Zelira Therapeutics (AU:ZLD) has released an update.

Zelira Therapeutics reported a net cash inflow of $586,000 for the quarter ending September 2024, driven primarily by $2,098,000 in proceeds from borrowings. However, the company faced significant cash outflows from operating activities amounting to $1,555,000, indicating a challenging financial quarter despite the influx from financing activities.

For further insights into AU:ZLD stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Australian Auto-Generated NewsdeskZelira Therapeutics Advances in FDA Trials and Product Development
TipRanks Australian Auto-Generated NewsdeskZelira Therapeutics Schedules Hybrid 2024 AGM
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App